Gazgalis Dimitris, Zaka Mehreen, Abbasi Bilal Haider, Logothetis Diomedes E, Mezei Mihaly, Cui Meng
Department of Pharmaceutical Sciences, Northeastern University School of Pharmacy, Boston, Massachusetts 02115, United States.
Department of Biotechnology, Quaid-i-Azam University, Islamabad 45320, Pakistan.
ACS Omega. 2020 Jun 10;5(24):14297-14307. doi: 10.1021/acsomega.0c00522. eCollection 2020 Jun 23.
The virtual high-throughput screening (vHTS) approach has been widely used for large database screening to identify potential lead compounds for drug discovery. Due to its high computational demands, docking that allows receptor flexibility has been a challenging problem for virtual screening. Therefore, the selection of protein target conformations is crucial to produce useful vHTS results. Since only a single protein structure is used to screen large databases in most vHTS studies, the main challenge is to reduce false negative rates in selecting compounds for in vitro tests. False negatives are most likely to occur when using apo structures or homology models of protein targets due to the small volume of the binding pocket formed by incorrect side-chain conformations. Even holo protein structures can exhibit high false negative rates due to ligand-induced fit effects, since the shape of the binding pocket highly depends on its bound ligand. To reduce false negative rates and improve success rates for vHTS in drug discovery, we have developed a new Monte Carlo-based approach that optimizes the binding pocket of protein targets. This newly developed Monte Carlo pocket optimization (MCPO) approach was assessed on several datasets showing promising results. The binding pocket optimization approach could be a useful tool for vHTS-based drug discovery, especially in cases when only apo structures or homology models are available.
虚拟高通量筛选(vHTS)方法已被广泛用于大型数据库筛选,以识别用于药物发现的潜在先导化合物。由于其对计算要求较高,允许受体具有灵活性的对接一直是虚拟筛选中的一个具有挑战性的问题。因此,蛋白质靶点构象的选择对于产生有用的vHTS结果至关重要。由于在大多数vHTS研究中仅使用单一蛋白质结构来筛选大型数据库,主要挑战在于降低在选择用于体外测试的化合物时的假阴性率。当使用蛋白质靶点的无配体结构或同源模型时,由于不正确的侧链构象形成的结合口袋体积较小,最容易出现假阴性。即使是全蛋白结构,由于配体诱导契合效应,也可能表现出较高的假阴性率,因为结合口袋的形状高度依赖于其结合的配体。为了降低假阴性率并提高药物发现中vHTS的成功率,我们开发了一种基于蒙特卡罗的新方法,该方法可优化蛋白质靶点的结合口袋。这种新开发的蒙特卡罗口袋优化(MCPO)方法在几个数据集上进行了评估,结果显示很有前景。结合口袋优化方法可能是基于vHTS的药物发现的有用工具,特别是在只有无配体结构或同源模型可用的情况下。